Skin tests of a novel nicotine patch, PHK-301p, in healthy male volunteers: Phase I, placebo-controlled study

Journal of Pharmacological Sciences

Volumn 102, Issue 1, 2006, Pages 72-76

  Irie, Shin ^a   Tsukikawa, Hiroshi ^a   Nabeshima, Toshitaka ^b   Usami, Makiko ^b   Karino, Tadaaki ^b   Komatsu, Shuichi ^c   Akasaki, Moriaki ^c  

^a Kyushu Clinical Pharmacology Research Clinic   (Japan)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c PFIZER INC   (United States)

Author keywords

Nicotine patch; Nicotine replacement therapy; Patch test; Skin reaction; Smoking cessation

Indexed keywords

NICOTINE PATCH; PHK 301 P; PLACEBO; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG SAFETY; ERYTHEMA; HUMAN; NICOTINE REPLACEMENT THERAPY; NORMAL HUMAN; PHOTOSENSITIVITY; PHYSICIAN; SKIN IRRITATION; SKIN MANIFESTATION; SKIN TEST; SOLAR URTICARIA; ULTRAVIOLET A RADIATION; VOLUNTEER;

EID: 33748967719     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0060422     Document Type: Article

References (13)

1. Silagy C, Lancaster T, Stead L, Mant D, Fowler G. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2004;(3):CD0001463.
2. Fiore MC, Bailey WC, Cohen SJ, Dorfman SF, Goldstein MG, Gritz ER, et al. Treating tobacco use and dependence - Clinical practice guideline: U.S. Department of Health and Human Services; 2000 Jun. Available from: http://www.surgeongeneral.gov/tobacco/
3. Sobue S, Sekiguchi K, Kikkawa H, Akasaki M, Irie S. Comparison of nicotine pharmacokinetics in healthy Japanese male smokers following application of the transdermal nicotine patch and cigarette smoking. Biol Pharm Bull. 2006;29:1068-1073.
4. Li Wan Po A. Transdermal nicotine in smoking cessation. A meta-analysis. Eur J Clin Pharmacol. 1993;45:519-528.
5. Greenland S, Satterfield MH, Lanes SF. A meta-analysis to assess the incidence of adverse effects associated with the transdermal nicotine patch. Drug Saf. 1998;18:297-308.
6. Imperial Cancer Research Fund General Practice Research Group. Effectiveness of a nicotine patch in helping people stop smoking: results of a randomized trial in general practice. BMJ. 1993;306:1304-1308.
7. Sugai T, Yoshiie H, Urae A. [Skin safety evaluation of Ba37142 (Nicotine TTS).] J Clin Ther Med. 1994;10 Suppl:83-89. (text in Japanese with English abstract)
8. Hayakawa R, Ninagawa Y. [Skin safety evaluation of nadifloxacin (OPC-7251) ointment.] Skin Res. 2000;42:509-513. (text in Japanese with English abstract)
9. Pirila V. Chamber test versus patch test for epicutaneous testing. Contact Dermatitis. 1975;1:48-52.
10. Sobue S, Sekiguchi K, Kikkawa H, Irie S. Effect of application sites and multiple doses on nicotine pharmacokinetics in healthy male Japanese smokers following application of the transdermal nicotine patch. J Clin Pharmacol. 2005;45:1391-1399.
11. Murphy M, Carmichael AJ. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol. 2000;1:361-368.
12. Bircher AJ, Howald H, Rufli T. Adverse skin reactions to nicotine in a transdermal therapeutic system. Contact Dermatitis. 1991;25:230-236.
13. Nieboer C, Bruynzeel DP, Boorsma DM. The effect of occlusion of the skin with transdermal therapeutic system on Langerhans' cells and the induction of skin irritation. Arch Dermatol. 1987;123:1499-1502.